David S. Hong, MD, on a Novel First-in-Class Agent Under Study in Non–Small Cell Lung Cancer

Posted: Tuesday, September 29, 2020

David S. Hong, MD, of The University of Texas MD Anderson Cancer Center, discusses his study findings on sotorasib, a first-in-class oral KRASG12C inhibitor, and the clinical implications of treating already heavily pretreated patients with non–small cell lung cancer.